DiaMedica Therapeutics (DMAC) News Today $4.57 -0.38 (-7.68%) Closing price 04:00 PM EasternExtended Trading$4.57 0.00 (-0.11%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Q1 Earnings Estimate for DMAC Issued By HC WainwrightMarch 23 at 1:13 AM | americanbankingnews.comEquities Analysts Set Expectations for DMAC Q1 EarningsDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for DiaMedica Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst M. Caufield expects that the company will poMarch 22 at 6:33 AM | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC WainwrightHC Wainwright raised their price target on DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday.March 20, 2025 | marketbeat.comDiaMedica Therapeutics price target raised to $10 from $7 at H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comDiamedica Therapeutics (DMAC) Gets a Buy from Lake StreetMarch 20, 2025 | markets.businessinsider.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comDiaMedica Therapeutics (NASDAQ:DMAC) Announces Earnings ResultsDiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01).March 18, 2025 | marketbeat.comDiaMedica Therapeutics reports FY24 EPS (60c), consensus (59c)March 17, 2025 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial ResultsMarch 17, 2025 | businesswire.comInsider Stock Buying Reaches US$9.00m On DiaMedica TherapeuticsMarch 17, 2025 | finance.yahoo.comDiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025March 11, 2025 | businesswire.comDiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on TuesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 21.1%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average trading volume of 113,800 shares, the short-interest ratio is presently 2.0 days.March 7, 2025 | marketbeat.comDiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of DirectorsFebruary 24, 2025 | finance.yahoo.comDiaMedica Therapeutics publishes DM199 data in StrokeFebruary 21, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)February 21, 2025 | markets.businessinsider.comDiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal StrokeFebruary 20, 2025 | finance.yahoo.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Drops By 8.4%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 191,900 shares, a drop of 8.4% from the January 15th total of 209,500 shares. Based on an average daily volume of 103,200 shares, the short-interest ratio is currently 1.9 days.February 18, 2025 | marketbeat.comDiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 11, 2025 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 222,800 shares, a growth of 14.5% from the December 31st total of 194,600 shares. Based on an average daily trading volume, of 93,700 shares, the days-to-cover ratio is presently 2.4 days.February 1, 2025 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Time to Sell?DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Here's What HappenedFebruary 1, 2025 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in DecemberDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average trading volume of 87,500 shares, the days-to-cover ratio is presently 2.2 days.December 29, 2024 | marketbeat.comIndividual investors are DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) biggest owners and were hit after market cap dropped US$26mDecember 19, 2024 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Diamedica Therapeutics (DMAC)December 18, 2024 | markets.businessinsider.comShort Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2%DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 151,500 shares, a drop of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the short-interest ratio is presently 1.8 days.December 15, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher - Should You Buy?DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 0.6% - Should You Buy?December 7, 2024 | marketbeat.comEnhanced Prospects for Diamedica Therapeutics with Trial Refinements and New InitiativesNovember 16, 2024 | markets.businessinsider.comDiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday.November 15, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comDiaMedica Therapeutics doses first patient in Phase 2 DM199 trialNovember 14, 2024 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | businesswire.comDiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select ConferenceNovember 13, 2024 | finance.yahoo.comPreview: DiaMedica Therapeutics's EarningsNovember 13, 2024 | benzinga.comDiaMedica Therapeutics (DMAC) to Release Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comDiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024November 6, 2024 | businesswire.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 152,300 shares, a growth of 10.0% from the September 15th total of 138,400 shares. Based on an average daily trading volume, of 54,000 shares, the days-to-cover ratio is presently 2.8 days.October 15, 2024 | marketbeat.comDiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of PreeclampsiaOctober 9, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright Forecasts (NASDAQ:DMAC)DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of DiaMedica Therapeutics in a report released on Monday, October 7th. HC Wainwright analyst M. Caufield expects that the company will post earnings ofOctober 9, 2024 | marketbeat.comOptimistic Outlook on DiaMedica Therapeutics’ Market Potential and Clinical AdvancementsOctober 8, 2024 | markets.businessinsider.comDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05mOctober 8, 2024 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of DiaMedica Therapeutics (DMAC) with Buy RecommendationOctober 8, 2024 | msn.comDiaMedica Therapeutics (NASDAQ:DMAC) Research Coverage Started at HC WainwrightHC Wainwright began coverage on shares of DiaMedica Therapeutics in a research note on Monday. They issued a "buy" rating and a $7.00 target price for the company.October 7, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7%DiaMedica Therapeutics (NASDAQ:DMAC) Trading 2.7% HigherSeptember 10, 2024 | marketbeat.comDiaMedica Therapeutics Upcoming Conference ParticipationSeptember 5, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 26.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,013,522 shares of the company's stock after acquiring an additionalAugust 19, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Receives Outperform Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday.August 16, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in JulyDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 144,200 shares, a decrease of 17.0% from the July 15th total of 173,700 shares. Based on an average daily trading volume, of 60,500 shares, the days-to-cover ratio is presently 2.4 days.August 16, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPSDiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period in the prior year, the firm posted ($0.16) EPS.August 10, 2024 | marketbeat.com Remove Ads Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address DMAC Media Mentions By Week DMAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DMAC News Sentiment▼0.460.68▲Average Medical News Sentiment DMAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DMAC Articles This Week▼121▲DMAC Articles Average Week Remove Ads Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Day One Biopharmaceuticals News Replimune Group News Oculis News Pharvaris News Cogent Biosciences News Avadel Pharmaceuticals News Evolus News Anavex Life Sciences News Avid Bioservices News uniQure News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DMAC) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts